A detailed history of Breakwater Capital Group transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Breakwater Capital Group holds 1,724 shares of VRTX stock, worth $853,828. This represents 0.18% of its overall portfolio holdings.

Number of Shares
1,724
Previous 1,594 8.16%
Holding current value
$853,828
Previous $666 Million 21.28%
% of portfolio
0.18%
Previous 0.17%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 26, 2024

BUY
$392.81 - $485.53 $51,065 - $63,118
130 Added 8.16%
1,724 $808 Million
Q1 2024

Apr 17, 2024

BUY
$407.69 - $446.08 $125,568 - $137,392
308 Added 23.95%
1,594 $666 Million
Q4 2023

Jan 23, 2024

BUY
$343.0 - $410.68 $107,702 - $128,953
314 Added 32.3%
1,286 $566 Million
Q3 2023

Nov 03, 2023

BUY
$338.18 - $362.46 $11,836 - $12,686
35 Added 3.74%
972 $359 Million
Q2 2023

Jul 24, 2023

BUY
$314.42 - $351.91 $294,611 - $329,739
937 New
937 $330 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $127B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Breakwater Capital Group Portfolio

Follow Breakwater Capital Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Breakwater Capital Group, based on Form 13F filings with the SEC.

News

Stay updated on Breakwater Capital Group with notifications on news.